← board
EVFM
distress 1/10 · well-funded / low risk$0.01-9%today-54% from 52w high
Lead: bacterial vaginosis
Revenue
pre-revenue
Liquidity
$1M
Runway
5.9 yrs
Shares 1y
+12%
Price & events
-18.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
-8.8%
1D
-8.8%
1W
-8.8%
1M
-8.8%
3M
-18.9%
6M
-18.9%
1Y
-27.0%
2Y
-100.0%
5Y
-100.0%
All
Overview
- Market Cap
- $967.47K
- Volume
- 63
- 52 Week Range
- $0.01 – $0.02
- Total Shares
- 132.53M
- Float Shares
- 132.53M
- Short %
- 11.01%
- % Held by Insiders
- 0.00%
- % Held by Institutions
- 0.00%
- RVOL
- 0.00x
- Beta
- -1.32
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 7
- 2026-04-24partnershipSOLOSEC · Exclusive distribution agreement for Sub-Saharan AfricaSEC 8-K
- 2025-10-20withdrawalTermination of merger agreement with Aditxt due to lack of shareholder approval.SEC 8-K
- summer 2025regulatory submissionFiled (NDA/BLA)SOLOSEC · Pharma 1 to file regulatory dossier for SOLOSEC in UAESEC 8-K
- 2025-05-19partnershipSOLOSEC · Exclusive license and supply agreement with Pharma 1 for Middle EastSEC 8-K
- Q3 2024regulatory submissionFiled (NDA/BLA)Phexxi · Pharma 1 anticipates filing UAE regulatory submission for Phexxi in Q3 2024.SEC 8-K
- 2024-07-17partnershipPhexxi · Exclusive license agreement with Pharma 1 for Middle East commercialization.SEC 8-K
- 2024-07-14partnershipSolosec · Evofem acquired Solosec (secnidazole) from Lupin in an asset purchase agreement closed July 14, 2024.SEC 8-K
Approved drugs (2)
- PHEXXCITRIC ACID2020 · Prescription
- SOLOSECSECNIDAZOLE2017 · Prescription
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors — bacterial vaginosis
- none identified
Recent news
- 2026-07-23Evofem (EVFM) Reaches Milestone in PHEXX Shipments - GuruFocus
- 2026-07-23Evofem Biosciences Celebrates Shipment of Its 500,000th Unit of PHEXX®, Representing Hormone-Free Protection from Unintended Pregnancy for 6 Million Acts of Sex - Yahoo Finance
- 2026-07-20Evofem Biosciences (EVFM) Investor presentation Summary - Quartr
- 2026-07-20Evofem Biosciences Updates Investors via New Presentation - TipRanks
- 2026-07-20Evofem Biosciences posts corporate slide deck to investor website - TradingView
- 2026-07-20Evofem Biosciences (EVFM) Investor presentation Summary - Quartr
- 2026-07-20EVFM: Innovative women's health products achieve growth, global expansion, and cost optimization - TradingView
- 2026-07-15Evofem Biosciences Enters New Subordinated Debt Agreement - TipRanks
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.